semaglutide cardiovascular news today risk #VisualAbstract: and Outcomes in Obesity without Diabetes New Science Suggests Semaglutide Improves – Semaglutide found to cut major

Breaking down the numbers further: 5% weight loss achieved : 95% with tirzepatide vs 79% with semaglutide 10% weight loss achieved : 89% with tirzepatide vs 61% with semaglutide 15% weight loss achieved : 77% with tirzepatide vs 39% with semaglutide 20% weight loss achieved : 62% with tirzepatide vs 23% with semaglutide Diabetes Management For patients with type 2 diabetes, both medications offer significant benefits, though tirzepatide shows a slight edge: HbA1c reduction : Tirzepatide typically lowers HbA1c by 2-2.5%, while semaglutide achieves 1-2% reduction Fasting glucose improvement : Both medications effectively lower fasting blood sugar Time in range : Patients on both medications spend more time with blood sugars in the target range Insulin sensitivity : Tirzepatide may provide greater improvements in insulin sensitivity Cardiovascular Benefits Semaglutide has established cardiovascular benefits with FDA approval for reducing heart attack, stroke, and cardiovascular death risk in patients with type 2 diabetes or obesity with established heart disease

Even if two vendors report identical purity levels, subtle differences in impurity profiles, actual peptide content, or formulation can affect research outcomes

Urinary electrolytes were also measured in the collected 24-hour urine

10 The American College of Cardiology/American Heart Association primary prevention of cardiovascular disease guideline supports the use of GLP-1 RAs in patients with T2D and high atherosclerotic CVD risk, but does not mention existing HF